Epic teams up with Amazon Pharmacy, Eli Lilly and Mark Cuban to launch prescription drug pricing tool
Epic teams up with Amazon Pharmacy, Eli Lilly and Mark Cuban to launch prescription drug pricing tool
Evidence dossier
Intelligence passport
Measured timeline
Who reported it (5)
-
Epic launches new Prescription Marketplace price transparency toolHealthcare IT News · 20h ago
-
Rx Marks the SpotHealth API Guy · 20h ago
-
Epic rolls out prescription price transparency toolModern Healthcare · 20h ago
-
-
Epic teams up with Amazon Pharmacy, Eli Lilly and Mark Cuban to launch prescription drug pricing toolFierce Healthcare · 20h ago
Where it stands
- Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: Epic teams up with Amazon Pharmacy, Eli Lilly and Mark Cuban to launch prescription drug pricing tool
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Patients can now compare pharmacy cash prices for prescriptions before leaving the doctor's office. Epic Systems, a leading healthcare software provider, has launched a new Prescription Marketplace price transparency tool in partnership with Amazon Pharmacy, Eli Lilly and Mark Cuban. The tool allows patients to compare cash prices for prescriptions across different pharmacies. Epic's move is seen as a response to growing concerns about prescription drug prices, which have been a major burden for many patients. However, the impact of this tool remains to be seen, as it is unclear how widely it will be adopted by healthcare providers and patients.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. Updated 2h ago.
Answered
Who is behind the new Prescription Marketplace price transparency tool?
Epic Systems, in partnership with Amazon Pharmacy, Eli Lilly and Mark Cuban
What does the tool allow patients to do?
Compare cash prices for prescriptions across different pharmacies
What is the goal of the tool?
To provide price transparency for prescription medications
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
From around our network
- Cage vs. Amazon: What an Actor's AI Waiver Actually Hands a Studio daybreakwire.com
- Apple, Samsung, Amazon 2026 tablets to buy: francoischarron.com world-today-news.com
Related trends
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics slashes 40% of staff after Lilly aborts a cancer partnership, sending its shares sharply lower.
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Novo Nordisk's shares dropped as Eli Lilly gains ground in GLP-1s
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
Viking Therapeutics stock surges 30% on positive obesity drug trial results.
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
700,000 seniors start GLP-1 treatments under Medicare, with 70% on Eli Lilly drugs
The company behind a new GLP-1 pill is betting $6.5 billion on Houston
Eli Lilly stakes $6.5 billion on a Houston plant as its GLP‑1 drugs dominate Medicare prescriptions
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
Novo Nordisk has signed an up to $1.4 billion licensing deal with Danish biotech Orbis Medicines to develop oral macrocycle drugs for cardiometabolic diseases.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.